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Background: The purpose of this article is to report on the quality of the existing evidence base regarding the
effectiveness of clinical pathway (CPW) research in the hospital setting. The analysis is based on a recently
published Cochrane review of the effectiveness of CPWs.
Methods: An integral component of the review process was a rigorous appraisal of the methodological quality of
published CPW evaluations. This allowed the identification of strengths and limitations of the evidence base for
CPW effectiveness. We followed the validated Cochrane Effective Practice and Organisation of Care Group (EPOC)
criteria for randomized and non-randomized clinical pathway evaluations. In addition, we tested the hypotheses
that simple pre-post studies tend to overestimate CPW effects reported.
Results: Out of the 260 primary studies meeting CPW content criteria, only 27 studies met the EPOC study design
criteria, with the majority of CPW studies (more than 70 %) excluded from the review on the basis that they were
simple pre-post evaluations, mostly comparing two or more annual patient cohorts. Methodologically poor study
designs are often used to evaluate CPWs and this compromises the quality of the existing evidence base.
Conclusions: Cochrane EPOC methodological criteria, including the selection of rigorous study designs along with
detailed descriptions of CPW development and implementation processes, are recommended for quantitative
evaluations to improve the evidence base for the use of CPWs in hospitals.Background
What are clinical pathways?
Clinical pathways (CPWs) are evidence-based multidis-
ciplinary care plans which describe the essential steps
needed in the care of patients with a specific clinical
problem. They are used to translate clinical guidelines
into local protocols and clinical practice [1]. Whereas
clinical guidelines provide generic recommendations,
CPWs are specifically tailored to the local hospital struc-
tures, systems and time-frames used.
Clinical pathways have been proposed as a strategy to
optimise resource allocation in a climate of increasing
healthcare costs [2]. Other terms used to describe clinical* Correspondence: thomas.rotter@maastrichtuniversity.nl
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Objectives
The first objective of this article is to report on the
methodological quality of the existing evidence base
regarding the effectiveness of CPW research in the hos-
pital setting. An international, multidisciplinary team of
researchers conducted a systematic review of the effect-
iveness of CPWs in hospitals, with the findings recently
published in the Cochrane library [3]. The second ob-
jective is to test the hypothesis that simple pre-post
studies tend to overestimate CPW effects reported.
Method
We followed the validated Cochrane Effective Practice
and Organisation of Care Group (EPOC) methodology
for considering and analysing studies [4]. The primary
systematic review aimed to catalogue the internationaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fessional practice, patient outcomes, length of hospital
stay and hospital costs. We searched the Database of
Abstracts of Reviews of Effectiveness, the Effective Prac-
tice and Organisation of Care Register, the Cochrane
Central Register of Controlled Trials and bibliographic
databases including MEDLINE, EMBASE, CINAHL,
NHS EED and Global Health. Details of the electronic
search strategy for the identification of studies are pre-
sented in detail in the EPOC review, recently published
in the Cochrane Library [3]. Our team developed and
validated five minimum criteria to define a CPW to en-
sure that only appropriate studies were sourced and
included in the review [5]. An integral component of the
review process was a rigorous appraisal of the study
designs and methodological quality of all relevant CPW
evaluations. This allowed the identification of strengths
and limitations of the evidence base for CPW effective-
ness with regard to the first study objective.
Assessment of study design
For the purpose of the systematic review on CPWs in
hospitals, four study designs were considered for inclu-
sion: randomized controlled trials (RCTs), controlled
clinical trials (CCTs), controlled before and after studies
(CBAs) and interrupted time series analysis (ITS).
While there are many well developed and well
accepted critical appraisal criteria for experimental stud-
ies, fewer exist for non-experimental studies such as
CBAs and ITS. Both designs are subject to a lack of con-
trol and high risk of bias so EPOC developed criteria to
facilitate their quality assessment and inclusion (where
appropriate) in systematic reviews. For example, CBAs
are required to have more than one control group and
ITS require at least three time points before and after an
intervention. Validated criteria for the assessment of
these designs have been developed by EPOC and are
available from the EPOC website [6] and the four differ-
ent study designs are briefly outlined in Table 1. In
addition, the simplified EPOC gold standard of study
designs considered for inclusion in the present review
are depicted in Figure 1[4].
Risk of bias assessment
We developed a quality assessment and data abstraction
instrument incorporating the EPOC risk of bias criteria
[4]. Quality assessment was conducted on full-text arti-
cles once initial literature searching and screening indi-
cated that articles were research-based and referred to a
CPW and were, subsequently, potentially relevant. The
EPOC approach for judging risk of bias of randomized
and non-randomized studies is a two-part assessment
tool, concerning specific domains and quality criteria
(i.e. RCTs: sequence generation, allocation concealment,blinding, et cetera). The validated risk of bias criteria can
be found in the Cochrane EPOC Group module [4] and
are presented in detail in additional file 1.
Comparison of CPW interventions
We compared patients managed according to CPW to
those managed by usual care, and patients treated within
a multifaceted intervention including a CPW compared
to usual care.
Secondary analysis
The aim of the secondary analysis was to determine
whether pre-post study design was associated with an
overestimate of the effects of CPW. Other researchers
also compared the findings of randomized evaluations
vs. non-randomized study designs and concluded that
such studies potentially overestimate the effects reported
and there were systematic differences between effects
estimated [7-9]. To test the hypothesis, we compared 14
primary studies [10-23], included in the Cochrane re-
view, grouped into category 1 (patients managed accord-
ing to CPW compared to usual care), and reporting on
length of stay (LOS) as the most commonly employed
outcome measure with a randomly selected sample of 14
excluded pre-post CPW evaluations also reporting LOS
[24-37]. The selection of a random sample of studies
was taken from those studies excluded on the basis of a
simple pre-post design not meeting EPOC quality criteria
(see Table 2). We used a computer generated random
sample (RAND function in Excel) [38] of 14 excluded pre-
post studies reporting LOS as a primary study outcome
[24-37].
Statistical pooling (meta-analysis)
A Cochrane web-based program, Review Manager
(RevMan), was used to calculate a pooled estimate of
the combined intervention effect on LOS, called
weighted mean difference (WMD) [39]. We used a ran-
dom effects model since this model estimates the effect
with consideration to the variance between studies, ra-
ther than ignoring heterogeneity by employing a fixed
effect model [40]. Statistical inconsistency within both
subgroups was assessed by calculating a test of hetero-
geneity (I square (I2)).
Results
All potentially relevant studies were assessed using the
CPW definition [5] and EPOC review inclusion criteria
for acceptable study designs [4]. Using two independent
reviewers, we rejected 2954 of the 3214 potential papers
and only 260 primary studies were initially identified as
potentially relevant and full text copies were retrieved.
Figure 2 illustrates the described trial flow.
Table 1 EPOC study designs considered for inclusion
Patient randomized
controlled trials
(P-RCT):
The individual patients are allocated by random to the intervention or control group. Individual randomisation
facilitates equally distributed patient characteristics and comparability. Only the exposure to the intervention should
be the factor that distinguishes between both groups.
Cluster randomized
controlled trials
(C-RCT):
This is a robust study design that prevents contamination of professionals by randomising groups of professionals
(i.e. different practices, wards or hospitals). However, this means the fundamental assumption of independence
is violated because patients within a cluster are more likely to respond in a similar manner. This lack of
independence, statistically called “intracluster correlation,” also means a specific adjustment for clustering effects is
required to assure comparability with individually randomized trials.
Non-randomized
controlled trials
(CCTs):
Patient or cluster trials where allocation to experimental and control groups is quasi-random (i.e. alternated allocation).
Controlled before
and after studies
(CBAs):
CBAs are experimental studies with two or more control groups compared with one or more experimental groups
but allocation is not random. Data is collected on the control and intervention groups before the intervention is
introduced and then further data is collected after the intervention has been introduced. The reliability of the
intervention effect is questionable because there may be unidentified differences between the experimental intervention
and control groups which may have modified the observed effect. Note: EPOC has recently changed the policy about
inclusion of CBA studies with only one intervention site. Specific details about design criteria can be found at the
website (www.epoc.cochrane.org)
Interrupted time
series designs
(ITS):
This represents a robust method of measuring the effect of an intervention as a trend over time. It is a useful design
when recruitment of a control cohort is impractical, e.g. due to changes in hospital policy. Three or more data points
are collected before and after the intervention as a minimum standard. The intervention effect is measured against
the pre-intervention trend.
Source: Bero L, Eccles M, Grimshaw J, Gruen RL, Mayhew A, Oxman AD, Tavender E, Zwarenstein M, Shepperd S, Paulsen E, Pantoja T, Lewin S, Ballini L. Cochrane
Effective Practice and Organisation of Care Group (Cochrane Group Module). About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). The Cochrane
Library. Oxford: John Wiley, 2009; adopted by the authors.
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of 2954) had to be excluded because they failed to meet
our definition of CPW. Table 2 illustrates the reasons for
exclusion following title and abstract review. Out of the
260 primary studies meeting CPW content criteria fol-
lowing review of the full text, only 27 studies met the
EPOC study design and risk of bias criteria.
Assessment of study design
Out of 27 CPW evaluations included, nineteen of the
included studies were randomised controlled trials
(RCTs) [10,11,13-22,41-48], including two cluster rando-
mised trials (C-RCT) [20,47]. Four studies were CBAs
[49-52], two were CCTs [12,23] and two ITS [53,54].
Of the original studies which met the CPW content
criteria, more than 70 % were excluded from the review
as they were simple pre-post evaluations, mostly com-
paring two or more yearly patient cohorts (see Table 3).
Risk of bias assessment
Out of the 228 studies excluded in phase two following
full text review (see Table 3) only four non-randomized
studies [55-58] and one randomised clinical study (RCT)
[59] were excluded because of high risk of bias. The
RCT from Bittinger (1995) did not meet EPOC quality
criteria as only 50 % of study patients were followed up
after randomization and there was a high risk of attrition
bias. Four time series studies were excluded as data was
not analyzed appropriately. The studies from Joiner(1996), Smith (1999), Summers (1998) and Warner
(2002) had a high risk of bias because no statistical con-
trol was used [55-58].
Table 3 illustrates the reasons for exclusion in stage
two after meeting CPW content criteria in stage one.Secondary analysis
In Figure 3 we provide the detailed results of the meth-
odological comparison of the 14 included primary studies
which utilised Cochrane EPOC study design quality cri-
teria [4] and reporting on LOS [10-23] vs. 14 randomly
selected pre-post studies excluded from the review and
reporting on LOS as a primary outcome [24-37]. We
observed considerable statistical inconsistency within
both subgroups of CPW studies, so the calculated esti-
mates in LOS per subgroup should be treated with caution
(I² = 62% Cochrane EPOC subgroup vs. 98% randomly
selected subgroup.)
We observed greater reported LOS effects within the
random subgroup of excluded pre-post studies after meet-
ing CPW content criteria (WMD – 2.85 (95%CI: – 3.58 to
– 2.11)), versus the pooled LOS data recently published
in the Cochrane library (group 1 clinical pathway vs.
usual care WMD – 1.23 (95%CI – 1.73 to – 0.72)) [3].
Moreover, the pre-post studies in the randomly selected
subgroup tend to report more consistently on signifi-
cant reductions in LOS (see Figure 3). Statistically, the
chi-squared test for subgroup differences also reached a
significant level (P= 0.0004).
Randomised controlled trial (RCT) 
2 or more groups, random allocation
Controlled clinical trial (CCT) 
As for a RCT but the allocation was quasi-random (eg. alternation, date of birth, patient 
identifier)
Controlled before and after study (CBA) 
3 or more groups but allocation to control or intervention was not random, and there are 
at least 2 control groups. 
Note: EPOC has recently changed the policy about inclusion of CBA studies with only one intervention site. Specific 
details about design criteria can be found at the website (www.epoc.cochrane.org) 
Interrupted time series (ITS)
For assessing a trend over time. No control group but must have a clear point in time 
that intervention was introduced, plus 3 data points before and after the intervention. 
Time 1 
Time 2 
Time 3 
Intervention introduced 
Time 4 
Time 5 
Time6
If none of these designs then paper is EXCLUDED.
Possible participants 
non-randomly allocated
to either 
Intervention group – 
one or more than one
group
Control group – must 
be more than one 
group
Control group – must 
be more than one 
group
Possible participants quasi-randomly
allocated to either 
Intervention group Control group 
Possible participants randomly
allocated to either
Intervention group Control group 
Figure 1 Simplified EPOC standard of study designs considered for inclusion in the present review. Source: Bero L, Eccles M, Grimshaw J,
Gruen RL, Mayhew A, Oxman AD, Tavender E, Zwarenstein M, Shepperd S, Paulsen E, Pantoja T, Lewin S, Ballini L. Cochrane Effective Practice and
Organisation of Care Group (Cochrane Group Module). About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). The Cochrane
Library. Oxford: John Wiley, 2009; adopted by the authors.
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Why is it important to critically appraise study designs in
a systematic review?
We followed the validated Cochrane EPOC criteria for
randomized and non-randomized CPW evaluations [4,6].
The finding that the vast majority of studies failed to
meet methodological quality criteria strongly indicatesTable 2 Reasons for exclusion stage one (n= 2954)
Reason Number %
Not CPW 2335 79.1
Not study 253 8.6
Not hospital 246 8.3
EPOC minimum study design criteria not met 89 3.0
Other (e.g. qualitative study) 31 1.0
Total 2954 100that low quality study designs are too often used to
evaluate CPWs and contribute very little to the evidence
base regarding CPWs.
Many of such excluded CPW evaluations claimed to pro-
vide evidence for the effectiveness of the pathway interven-
tion under consideration but, with a methodologically weak
study design, it remains unclear if the reported effect was
really attributable to the CPW effectiveness or any other
unknown factors. Possible confounding factors might have
been the case-mix introduction, hospital quality improve-
ment initiatives or changes in hospital policy [2]. The un-
controlled nature and exposure to bias convey that such
studies contribute very little to the evidence-base.Implications of including weak study designs
Based on our review experience, we reaffirm that uncon-
trolled pre-post designs are commonly used to evaluate
Figure 2 Trial flow.
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misleading and contribute little to understanding the
reported effects of pathways. Considering the second ob-
jective of this article, the meta-analytic comparison sup-
ports other evidence [7-9] that simple pre-post study
designs tend to overestimate intervention effects reported.
There is a place for well designed process-evaluations
also referred to as interrupted time series (ITS) to ex-
plore and provide more insights into the varying path-
way components and their causal effectiveness to
determine how CPW interventions actually work. Care-
fully designed time series studies are less resource-
intensive than RCTs, do not require a control group,Table 3 Reasons for exclusion following full text review
(n =228)
Reason Number %
Not CPW 38 16.7
Simple pre-/post evaluations 160 70.2
High risk of bias 5 (1RCT) 2.2
Not study 14 6.1
Not hospital 11 4.8
Total 228 100and allow for the use of retrospective data. While requir-
ing more advanced statistical techniques than simple
pre-post studies, ITS supports research outcomes that
are more likely to contribute to the evidence base, in-
cluding systematic reviews. Better designed, conducted
and reported CPW evaluations will contribute to a bet-
ter understanding of the key elements of CPWs that im-
pact on patient, provider and economic outcomes.
Limitations
The majority of included studies employed LOS as a
performance measure. Hence, we compared the magni-
tudes of CPW effects on length of stay (n = 14 primary
studies) rather than patient outcomes such as mortality
(n= 4 studies) or in-hospital complications (n= 5 studies)
[3]. The low number of primary CPW evaluations
included in the review which reported on patient out-
comes prevented further testing of the robustness of this
methodological comparison.
Conclusion
Cochrane EPOC methodological inclusion criteria should
be considered for quantitative evaluations into the impact
of CPWs in hospitals. Based on our review experience, the
EPOC methodological gold standard is infrequently
Figure 3 Comparison meta analysis LOS COCHRANE vs. Excluded pre-post studies.
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hereby contribute significantly to the understanding of
factors associated with the reported effects of clinical
pathways in hospitals by incorporating EPOC criteria into
study design. Whilst experimental methods such as rando-
mised trials are recommended they may be considered be-
yond the capacity of many clinicians and researchers. A
well designed evaluation such as ITS or CBA that meets
the EPOC gold standard methodological criteria can pro-
duce meaningful, rigorous results with the use of rela-
tively few resources. In terms of the second study
objective, the methodological comparison of Cochrane
vs. non Cochrane study designs (see Figure 3) also sup-
port the finding that simple pre-post study designs tend
to overestimate CPW effects reported.Additional file
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